Capital Cell, an investment crowdfunding platform that describes itself as the first European crowdfunding platform for biotech projects, has recieved regulatory approval from the Comisión Nacional del Mercado de Valores (CNMV). According to a statement on their site, after ten months of audits, interviews and documentation they have received approval to operate as a “Participatory Financing Platform.”
According to Capital Cell;
“We are extremely pleased to have overcome the lengthy and surprisingly tough authorization process, and we can assure investors that Capital Cell has the approval of the regulatory body and will operate under a strict supervisory regime .
At some point we will issue a official statement , but for now we have three days of very intense paperwork.”
Capital Cell is now one of several investment platforms that have received the stamp of certification from the Spanish regulatory officials.
Ultima hora… CNMV nos ha autorizado @CapitalCellNet https://t.co/GbrVglIUQZ
— Capital Cell (@CapitalCellNet) July 25, 2016
